In the fiscal year ending March 2026, an impairment loss on fixed assets of 2,117 million yen was recorded as an extraordinary loss and reflected in the financial summary.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2664","jir_company_name":"Kawachi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-04-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/2664-20260428-02.pdf","jir_short_summary":"In the fiscal year ending March 2026, an impairment loss on fixed assets of 2,117 million yen was recorded as an extraordinary loss and reflected in the financial summary.","jir_summary":"### Regarding the Recording of Extraordinary Loss\nKawachi Pharmaceutical Co., Ltd. recorded an impairment loss of 2,117 million yen as an extraordinary loss in the fiscal year ending March 2026 (March 16, 2025 to March 15, 2026) after reviewing the recoverability of fixed assets. The breakdown consists of 1,960 million yen for buildings and structures and 210 million yen for other assets.\n\n### Impact on Business Performance\nThis extraordinary loss has been reflected in the consolidated financial summary for the fiscal year ending March 2026, published on the same day, negatively impacting business results. However, the document does not specify the exact impact on operating income or net income.","jir_financial_highlights":"Extraordinary Loss (Impairment Loss): 2,117 million yen (Unknown)\nImpairment Loss on Buildings and Structures: 1,960 million yen (Unknown)\nOther Fixed Assets Impairment Loss: 210 million yen (Unknown)","jir_category":"","jir_hashtags":"#KawachiPharmaceutical, #financial_summary, #JapaneseStocks","jir_key_figures":"Extraordinary Loss (Impairment Loss): 2,117 million yen\nImpairment Loss on Buildings and Structures: 1,960 million yen\nOther Fixed Assets Impairment Loss: 210 million yen","jir_meta_title":"[Kawachi Pharmaceutical] Recording of 2.1 Billion Yen Impairment Loss on Fixed Assets for Fiscal Year Ending March 2026","jir_meta_description":"Kawachi Pharmaceutical Co., Ltd. recorded an impairment loss on fixed assets totaling 2,117 million yen as an extraordinary loss for the fiscal year ending March 2026. The impact is reflected in the financial summary, affecting earnings.","jir_og_title":"[Kawachi Pharmaceutical] Recording of 2.1 Billion Yen Impairment Loss on Fixed Assets for Fiscal Year Ending March 2026","jir_og_description":"Kawachi Pharmaceutical recorded an impairment loss on fixed assets of 2,117 million yen in the fiscal year ending March 2026. This has been reflected in the financial summary and has impacted business performance.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16960,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-43680","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n